Oramed's oral insulin candidate fails in late-stage trial
Oramed Pharmaceuticals stock dived on the exchange after it was announced that the company’s oral insulin candidate did not meet its target in a phase III study.
by albert rønning-andersson, translated by daniel pedersen
Dreams of developing an oral insulin treatment appears dead for Israeli pharmaceutical firm Oramed Pharmaceuticals, which announced in a Thursday press release that its drug candidate, ORMD-0801, has failed in a late-stage study.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
